Andrew Cheng
CIK 1778307 · President and CEO · last filed 2026-05-26
Andrew Cheng is a President and CEO who has filed 82 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for VERA, was dated May 26, 2026. Across all open-market trades the lifetime net is −$43.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $599.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$599.1K
3
82
-$43.39M
Holdings By Company
Recent Filings
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-26 | VERA | Grant (A) | — | $0 | EDGAR |
| 2025-12-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Disp (D) | −436,837 | $0 | EDGAR |
| 2025-11-21 | Akero Therapeutics, Inc. (AKRO) Delisted | Gift (G) | −74,538 | $0 | EDGAR |
| 2025-11-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Gift (G) | −14,739 | $0 | EDGAR |
| 2025-10-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | — | -$1.02M | EDGAR |
| 2025-10-09 | Akero Therapeutics, Inc. (AKRO) Delisted | Exer (M) | +52,212 | $32.1K | EDGAR |
| 2025-09-12 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | −16,855 | -$1.25M | EDGAR |
| 2025-08-13 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −30,000 | -$1.46M | EDGAR |
| 2025-07-11 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −30,000 | -$1.53M | EDGAR |
| 2025-07-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | +890 | $21.2K | EDGAR |